Healthcare / BiotechnologyParis
$0.39
-0.00 (-1.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
1.3x
↓EV/EBITDA
2.1x
↓ROE
10.4%
↑Gross Margin
3726.1%
↑Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-68.0%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $261148.1 · net income $5.5M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $261148.06 | $261148.06 | $207040.00 | $1.1M | $8.0M |
| Net Income | $5.5M | $5.5M | $-7.2M | $-8.1M | $-231181.00 |
| EBITDA | $6.1M | $6.1M | $-7.3M | $-9.5M | $-1.4M |
| EPS | — | — | — | -0.49 | -0.01 |
| Gross Margin | 3726.1% | 3726.1% | -3039.8% | -615.4% | 5.8% |
| Operating Margin | 3146.9% | 3146.9% | -3770.8% | -927.4% | -20.2% |
| Net Margin | 2098.3% | 2098.3% | -3482.2% | -754.6% | -2.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | -17.65 | 2.39 | 0.22 |
| Current Ratio | 1.86 | 1.86 | — | — | — |
| Returns | |||||
| ROE | 10.4% | 10.4% | 1679.0% | -219.2% | -2.0% |
| Valuation | |||||
| P/E | 1.28 | 1.28 | — | — | — |
| EV/EBITDA | 2.15 | 2.15 | — | — | — |
| P/B | 0.13 | 0.13 | — | 8.56 | 2.32 |
| Growth & Yield | |||||
| Revenue Growth | 26.1% | 26.1% | -80.7% | -86.6% | — |
| EPS Growth | — | — | — | -3390.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.7%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
+16.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.